Synopsis:
Fermenta Biotech secured a patent for its plant-based Vitamin D3, reinforcing its leadership in sustainable, vegan nutrition and unlocking growth opportunities in nutraceutical and fortified food markets.
During Friday’s trading session, shares of India’s leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for global markets surged nearly 7.3 percent on BSE, after securing a patent for plant-based Vitamin D3 from the Indian Patent Office.
At 02:11 p.m., the shares of Fermenta Biotech Limited were trading in the green at Rs. 367.55 on BSE, up by around 6.5 percent, as against its previous closing price of Rs. 345.2, with a market cap of Rs. 1,082 crores. The stock has delivered positive returns of around 30 percent in the last one year, and has gained by over 4 percent in the last one month.
What’s the News
According to the latest filings on the BSE, Fermenta Biotech Limited announced that the Indian Patent Office has formally granted a patent for its invention of a plant-based Vitamin D3. This newly granted patent protects Fermenta’s proprietary production process for plant-based Vitamin D3, representing a major milestone in its innovation pipeline and further reinforcing its position in the global Vitamin D3 industry.
This market-leading vegan solution addresses the growing global demand for ethically sourced and sustainable nutritional products, positioning Fermenta at the forefront of the plant-based nutrition movement.
By facilitating the production of fully vegan and vegetarian-friendly Vitamin D3, this innovation unlocks new opportunities in the nutraceutical and food fortification markets, where sustainable, plant-based ingredients are increasingly sought after and commanding premium pricing and expanded market presence.
Financials & more
Fermenta Biotech reported a significant growth in its revenue from operations, showing a year-on-year increase of around 74 percent from Rs. 78 crores in Q1 FY25 to Rs. 136 crores in Q1 FY26. Similarly, the company achieved a strong turnaround, shifting from a net loss of Rs. 6 crores in Q1 FY25 to a net profit of Rs. 22 crores in Q1 FY26.
Fermenta Biotech Limited, formerly known as DIL Limited, is engaged in the business of manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations and environmental solution products and renting and selling of properties, serving both domestic and international markets. The company is among the world’s top 3 manufacturers of Vitamin D3 and has strategic investments in subsidiaries primarily dealing in manufacturing and marketing bulk drugs.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
